AstraZeneca and Sino Biopharmaceutical's subsidiary CTTQ have signed an exclusive licence agreement for TQC3721.

Evogene and Tel Aviv University’s BCDD have partnered to expedite small-molecule drug discovery originating from Israeli academic research.

The FDA is taking action to curb the illicit online trade of unregulated and unapproved ketamine products through a slew of warning letters.

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.

The US FDA has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for CMT2S.

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off mark ...

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

The UK Government has prioritised life science sector growth, but industry members have called for more funding.

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.